References
- Ampyra® (dalfampridine) extended release tablets [package insert]. Ardsley, NY, USA: Acorda Therapeutics Inc., 2011
- Goodman AD, Brown TR, Krupp L, et al. Sustained release of oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373:732-8
- Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010;68:494-502
- Weir S, Torkin R, Henney HR. Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with MS. Curr Med Res Opin 2012;in press
- Smith W, Swan S, Marbury T, Henney HR. Single-dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment. J Clin Pharmacol 2010;50:151-9
- Evenhuis J, Agoston S, Salt PJ, et al. Pharmacokinetics of 4-aminopyridine in human volunteers. A preliminary study using a new GLC method for its estimation. Br J Anaesth 1981;53:567-70
- Uges DR, Sohn YJ, Greijdanus B, et al. 4-Aminopyridine kinetics. Clin Pharmacol Ther 1982;31:587-93
- Caggiano A, Blight A, Parry T. Identification of metabolites of dalfampridine (4-aminopyridine) in dog and rat. J Drug Assessment 2013;2:72-80
- Blight AR, Henney HR. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. Clin Ther 2009;31:328-35
- Gelboin HV, Krausz KW, Gonzalez FJ, Yang TJ. Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery. Trends Pharmacol Sci 1999;20:432-8
- Shou M, Lu T, Krausz KW, et al. Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism. Eur J Pharmacol 2000;394:199-209